Literature DB >> 20185428

Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004.

V Leimane1, G Dravniece, V Riekstina, I Sture, S Kammerer, M P Chen, G Skenders, T H Holtz.   

Abstract

In the present study, we characterised drug-resistance patterns, compared treatment outcome between extensively and nonextensively drug-resistant tuberculosis (non-XDR-TB) cases, and assessed risk factors for poor outcome in a high-prevalence country that screens all TB patients for first-line anti-TB drug resistance. We reviewed drug susceptibility test results among all pulmonary TB cases in Latvia diagnosed from 2000-2004, as well as demographic and clinical characteristics, drug-resistance patterns, and treatment outcomes. During the 5-yr period, 1,027 multidrug-resistant tuberculosis (MDR-TB) cases initiated treatment. Among all cases, the proportion that experienced an outcome of cure or completion increased from 66.2 to 70.2% (p = 0.06 for linear trend). Among the 48 (4.7%) XDR-TB cases, 18 (38%) were cured, four (8%) died, three (6%) defaulted, and treatment failed in 23 (48%). In proportional-hazards analysis, characteristics significantly associated with poor outcome included XDR-TB, being retired, presence of bilateral cavitation, and previous MDR-TB treatment history for those aged ≥55 yrs. Overall, treatment success among all MDR-TB cases increased over time. Strategies to prevent transmission of XDR-TB and to further improve treatment outcome are crucial for the future of TB control in Latvia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20185428     DOI: 10.1183/09031936.00003710

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  39 in total

Review 1.  Surgical treatment of drug-resistant tuberculosis.

Authors:  Russell R Kempker; Sergo Vashakidze; Nelly Solomonia; Nino Dzidzikashvili; Henry M Blumberg
Journal:  Lancet Infect Dis       Date:  2012-02       Impact factor: 25.071

2.  Performance of the GenoType® MTBDRPlus assay in routine settings: a multicenter study.

Authors:  S Mironova; E Pimkina; I Kontsevaya; V Nikolayevskyy; Y Balabanova; G Skenders; T Kummik; F Drobniewski
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-25       Impact factor: 3.267

Review 3.  Targeting multidrug-resistant tuberculosis (MDR-TB) by therapeutic vaccines.

Authors:  Satria A Prabowo; Matthias I Gröschel; Ed D L Schmidt; Alena Skrahina; Traian Mihaescu; Serap Hastürk; Rotislav Mitrofanov; Edita Pimkina; Ildikó Visontai; Bouke de Jong; John L Stanford; Père-Joan Cardona; Stefan H E Kaufmann; Tjip S van der Werf
Journal:  Med Microbiol Immunol       Date:  2012-11-10       Impact factor: 3.402

4.  Microevolution of extensively drug-resistant tuberculosis in Russia.

Authors:  Nicola Casali; Vladyslav Nikolayevskyy; Yanina Balabanova; Olga Ignatyeva; Irina Kontsevaya; Simon R Harris; Stephen D Bentley; Julian Parkhill; Sergey Nejentsev; Sven E Hoffner; Rolf D Horstmann; Timothy Brown; Francis Drobniewski
Journal:  Genome Res       Date:  2012-01-31       Impact factor: 9.043

5.  Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis.

Authors:  G B Migliori; G Sotgiu; N R Gandhi; D Falzon; K DeRiemer; R Centis; M G Hollm-Delgado; D Palmero; C Pérez-Guzmán; M H Vargas; L D'Ambrosio; A Spanevello; M Bauer; E D Chan; H S Schaaf; S Keshavjee; T H Holtz; D Menzies
Journal:  Eur Respir J       Date:  2012-10-11       Impact factor: 16.671

6.  A close-up on the epidemiology and transmission of multidrug-resistant tuberculosis in Poland.

Authors:  T Jagielski; A Brzostek; A van Belkum; J Dziadek; E Augustynowicz-Kopeć; Z Zwolska
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-07-20       Impact factor: 3.267

7.  Map the gap: missing children with drug-resistant tuberculosis.

Authors:  C M Yuen; C A Rodriguez; S Keshavjee; M C Becerra
Journal:  Public Health Action       Date:  2015-03-21

8.  Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Authors:  Zhiyi Lan; Nafees Ahmad; Parvaneh Baghaei; Linda Barkane; Andrea Benedetti; Sarah K Brode; James C M Brust; Jonathon R Campbell; Vicky Wai Lai Chang; Dennis Falzon; Lorenzo Guglielmetti; Petros Isaakidis; Russell R Kempker; Maia Kipiani; Liga Kuksa; Christoph Lange; Rafael Laniado-Laborín; Payam Nahid; Denise Rodrigues; Rupak Singla; Zarir F Udwadia; Dick Menzies
Journal:  Lancet Respir Med       Date:  2020-03-17       Impact factor: 30.700

9.  Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes.

Authors:  Dennis Falzon; Neel Gandhi; Giovanni B Migliori; Giovanni Sotgiu; Helen S Cox; Timothy H Holtz; Maria-Graciela Hollm-Delgado; Salmaan Keshavjee; Kathryn DeRiemer; Rosella Centis; Lia D'Ambrosio; Christoph G Lange; Melissa Bauer; Dick Menzies
Journal:  Eur Respir J       Date:  2012-10-25       Impact factor: 16.671

10.  Prevalence and genetic characterization of second-line drug-resistant and extensively drug-resistant Mycobacterium tuberculosis in Rural China.

Authors:  Yi Hu; Sven Hoffner; Linlin Wu; Qi Zhao; Weili Jiang; Biao Xu
Journal:  Antimicrob Agents Chemother       Date:  2013-06-03       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.